Bundibugyo Ebolavirus Outbreak in Africa: Going from Bad to Worse

“The first month of this Ebola outbreak was already the worst on record.”

World Health Organization

“The current outbreak reinforces the principle that a successful response to filovirus disease requires integration of medical countermeasures, clinical care, surveillance, diagnostics, and coordinated multinational public health operations.”

Nancy J. Sullivan, ScD, New England Journal of Medicine, June 24, 2026

For half a century, Ebola virus disease (EVD) has periodically devastated Central and West Africa. No Ebola epidemic, however, has tested the world’s response infrastructure quite like the outbreak that began spreading through the Democratic Republic of the Congo (DRC) and Uganda this past spring—an outbreak that has developed into a catastrophe as healthcare providers await a vaccine and antiviral medication. By July 15, 2026, the World Health Organization (WHO) had confirmed 2,124 cases and 828 deaths.

It has been less than two months since my previous post on this outbreak. (Peterson, P., “Ebola Virus Strikes Terror Once Again,” Germ Gems, May 27, 2026). Nonetheless, as this outbreak is expanding very rapidly and controlling it requires enormous support from the global health community, I thought it important to highlight some of the most pressing challenges this outbreak poses.

Ebola virus disease (a recap). Orthoebolaviruses are members of the highly lethal RNA filovirus family Filoviridae. Once in the body, these viruses target immune cells and blood vessels and are capable of causing severe hemorrhagic fever, which is characterized by systemic inflammation, vascular leakage, multi-organ failure and associated with high mortality.

There are six known species of the genus Orthoebolavirus; four cause disease in humans and three of these are highly lethal. The highly lethal species are: Orthoebolavirus zairenses (Zaire virus or Ebola virus); Orthoebolavirus sudanense (Sudan virus); and Orthoebolavirus bundibugyoense (Bundibugyo virus).

Ebola is a zoonotic infection, meaning it originates in animals and then can be transmitted to humans. The elusive animal reservoir for the Ebola virus (EV) is most likely fruit bats.

Even though EV is not spread through the air (by aerosols), EVD is highly contagious and can affect a large number of people. People can be infected with the EV through contact with a fruit bat or contact with a non-primate animal infected with the virus. Person-to-person contact can occur through direct contact with the bodily fluids of infected individuals, be they living or having died from EVD. (The virus remains highly active after death.) The EVD mortality rate ranges from 25% up to 90% depending on the specific viral strain and access to early supportive care.

EVD is hard to diagnosis as the initial symptoms of Ebola, like all filovirus infections, are nonspecific and overlap with other viral infections that are endemic in central Africa. (Sullivan, N.J., “Bundibugyo Virus Disease in 2026—Clinical and Public Health Responses,” The New England Journal of Medicine, July 16, 2026). The early symptoms resemble influenza or malaria, that is, fever, fatigue, headache and loss of appetite, and usually begin suddenly after an incubation period of about 2-21 days after contact with the virus. These are followed by vomiting, profuse diarrhea, abdominal pain, and, in fatal cases, by liver and kidney disfunction, hemorrhage, shock, and death. These manifestations provide “little clinical specificity during the early stages of disease, when intervention is important.” A definitive diagnosis depends on laboratory testing; molecular assays remain the cornerstone of diagnosis.  

Ervebo is the one vaccine that is available and effective again the Zaire virus. (Adepoju, P., “Ebola vaccines exist, but not for the strain in the current outbreak, Scientific American, May 20, 2026). But, there is no licensed vaccine or treatment for either Sudan virus or Bundibugyo virus.

The current Ebola outbreak. Bundibugyo virus, a relatively rare orthoebolavirus, is the cause of the current outbreak in the DRC and Uganda. This virus has caused only two previously recognized disease outbreaks. But, as this outbreak has shown, Bundibugyo virus is capable of producing severe epidemic disease with substantial mortality.

This outbreak is already the third largest in history and the fastest growing—over 2000 cases including over 700 deaths were recorded in the past two months. (Soucheray, S., “Ebola cases surge past 2,000, now fastest growing outbreak in history,” CIDRAP News, July 15, 2026). As the WHO health emergencies chief Chikwe Ihekweazu said, “We’ve seen the fastest growth in a single month since the outbreak started and of all the Ebola outbreaks that we have managed. You have to image that this is a fire. There’s something driving the fire in its heart, and it’s also expanding at the same time.” 

The challenges. There are many factors that make this outbreak extraordinary and challenging to control. A recent Lancet article lists these five:

1. Cause: The outbreak is caused by the Bundibugyo virus for which there is no virus-specific therapeutics or vaccines thereby depriving response teams of crucial tools for breaking the chain of transmission and reducing disease fatality;

2. Area: The outbreak is occurring in both urban and rural areas, each with special challenges—rapid spread through urban areas with informal settlements and high population mobility and insufficient medical infrastructure in rural areas;

3. Epicenter: The epicenter of the outbreak is located in a province that shares borders with three other provinces and two countries thereby increasing the risk of national and regional spread;

4. Population affected: The outbreak is occurring in “areas affected by insecurity, population displacement, and mining-related population movement all of which increase the risk of transmission”; and

5. Community resistance: Ituri province, the epicenter of this outbreak and one of the provinces affected by the 2018-2020 Ebola outbreak, has a “history of high community resistance, especially against safe and dignified burials due to deeply entrenched cultural and spiritual funeral traditions.”

(Mwamaba, D., et al., “Bundibugyo virus disease outbreak in Ituri, Democratic Republic of the Congo,” The Lancet, June 13, 2026).

Compounding this situation is the fact that on July 6, 2026, frontline healthcare workers at the epicenter of this outbreak left their jobs at clinics and treatment centers amidst the growing outbreak. (Soucheray, S., “Ebola workers strike as CDC head says agency’s response will last months,” CIDRAP News, July 8, 2026). The workers claimed they had not been paid wages or bonuses since the outbreak was declared on May 15, 2026 and that they were fighting this outbreak with inadequate equipment. Although some workers recently returned to work, the situation remains highly volatile.

Not if, but when. The Bundibugyo virus outbreak in the DRC and Uganda exposes once again the fragility of epidemic preparedness across sub-Saharan Africa.  The U.S. has committed at least several hundred million dollars to this outbreak, with the CDC supplying $107 million alone in emergency funding.

But, as the authors of a recent Lancet article wrote: “International partners must also recognize that epidemic preparedness in sub-Saharan Africa is not a charity but global health security. Until equitable investments in prevention, research and resilient  health-care systems become a priority, recurrent Ebola virus disease outbreaks in Central Africa will not be a question of if, but when.” (Riberio, H.L., et al., “Ebola Outbreaks in DR Congo and Uganda: until when?,” The Lancet, June 13, 2026).